Stage 1: History of Postpartum Ecchymoses & Acute Joint Pain (Timestamp: 8 Weeks Postpartum)
A 32-year-old woman (residing in Delhi NCR, homemaker, 8 weeks postpartum following an uncomplicated first pregnancy and normal vaginal delivery) presents with a 3-week history of spontaneous extensive ecchymoses on her arms, legs, and lower back, and 1 week of severe pain and swelling in her right elbow and both knees.
HPI:
- Onset: Spontaneous bruising began shortly after a mild, self-limiting sore throat and coryza 3 weeks prior.
- 1 Week Prior: Progressive right elbow pain and bilateral knee pain. Fatigue present, but no fevers, night sweats, weight loss, epistaxis, bleeding on brushing teeth, hematuria, or gastrointestinal bleeding.
- Obstetric History: Delivered a healthy full-term infant boy 8 weeks prior. No past history of bleeding or autoimmune disorders. Medications: Multivitamin only.
Hello, Chief Resident here.
Key Findings: A 32-year-old female, 8 weeks postpartum, with acute spontaneous extensive ecchymoses and joint pain/swelling (suspected hemarthrosis) following a viral prodrome, without prior personal or family bleeding history.
Differential Diagnoses:
1. Acquired Hemophilia A (AHA) (60%): Classic postpartum presentation (typically 1–4 months post-delivery) with autoantibodies against Factor VIII, leading to large ecchymoses, deep tissue bleeding, and joint involvement.
2. Immune Thrombocytopenia (ITP) (20%): Common post-viral or postpartum presentation causing cutaneous bleeding, though hemarthrosis is less characteristic.
3. Acquired von Willebrand Syndrome (10%): Autoimmune-mediated clearance of vWF presenting with mucocutaneous and soft tissue bleeding.
4. Postpartum Autoimmune Coagulopathy / SLE (10%): New-onset systemic autoimmunity causing acquired factor inhibitors or complex coagulopathy.
Prioritized Tests:
1. CBC with Peripheral Blood Smear: Assess platelet count and exclude microangiopathic hemolysis.
2. Coagulation Panel (PT/INR, aPTT, Fibrinogen): Expect an isolated prolonged aPTT in AHA.
3. 1:1 aPTT Mixing Study (Immediate & Incubated): Differentiate factor deficiency from a time-dependent inhibitor.
4. Factor VIII Activity & Bethesda Assay: Confirm specific factor reduction and quantify inhibitor titers.
5. Autoimmune Panel (ANA, Anti-dsDNA, Antiphospholipid Antibodies): Identify underlying autoimmune pathology.
Hello Attending Consultant here
Critique: Solid prioritization of AHA, but overweights ITP (hemarthroses atypical) and under-emphasizes need for urgent hemostatic control. Mixing study timing critical; Bethesda alone insufficient without Nijmegen modification. Autoimmune panel secondary—secure diagnosis first. No mention of inhibitor bypass agents or immunosuppression staging.
Top 3 DDx:
1. Postpartum acquired hemophilia A (FVIII inhibitor)
2. Acquired vWD (autoimmune)
3. Lupus anticoagulant-hypoprothrombinemia syndrome
Specific points:
1. Add FVIII, FIX, FXI, FXII levels + vWF Ag/activity immediately.
2. Perform Nijmegen-Bethesda; quantify titer pre-therapy.
3. Initiate rFVIIa or aPCC empirically if bleeding progresses—do not await titers.
4. Screen for lymphoproliferative disease (SPEP, CT if indicated).
5. Start steroids + rituximab early once AHA confirmed; avoid FVIII concentrates if high-titer.
6. Serial aPTT/FVIII to guide weaning.
7. Exclude retained products/endometritis as antigenic trigger.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Acquired Hemophilia A (AHA), postpartum subtype — a Factor VIII autoantibody emerging after delivery, presenting classically 1–4 months postpartum with spontaneous ecchymoses, soft-tissue bleeding, and hemarthroses in a patient with no prior bleeding diathesis.
Key Pivot: The combination of postpartum timing + deep tissue/joint bleeding + absence of mucosal bleeding or thrombocytopenic symptoms shifts suspicion away from platelet disorders toward an acquired factor inhibitor.
Differentials:
- AHA — best fit; accounts for all findings including hemarthrosis.
- ITP — post-viral/postpartum ecchymoses fit, but ITP causes mucocutaneous bleeding, not hemarthroses. Exclude with CBC.
- Acquired von Willebrand syndrome — plausible, but typically mucocutaneous; hemarthrosis is uncommon.
- Lupus anticoagulant–hypoprothrombinemia syndrome — rare; post-viral trigger fits, but check PT and factor II.
Most Important Next Move: CBC, PT/aPTT with immediate and incubated mixing study, Factor VIII activity, and Bethesda/Nijmegen inhibitor titer. Expect isolated prolonged aPTT failing to correct on mixing. Involve hematology urgently; do not delay hemostatic therapy if bleeding progresses.
Teaching Pearl: Postpartum AHA is the classic demographic; unlike congenital hemophilia, bleeding is often more cutaneous/soft-tissue than articular, and the aPTT shows a time- and temperature-dependent inhibitor pattern on mixing.
Stage 2: Physical Exam & Isolated Severely Prolonged aPTT (Timestamp: Admission / Day 1)
Physical Exam: Afebrile (37.2°C), HR 72 bpm, BP 120/82 mmHg, RR 14/min, SpO2 98% on room air. Anicteric, pink conjunctivae, no oral petechiae/purpura. Heart/lung/abdominal exams normal, no organomegaly. Large confluent ecchymoses over calves, anterior thighs, arms, and lower back. Right elbow warm, swollen, flexion restricted to 100°. Both knees warm with restricted ROM (hemarthroses!).
Initial Laboratory Workup:
- CBC & Smear: WBC 9,900/µL (75.8% neutrophils, 19% lymphocytes), Hemoglobin 12.1 g/dL (Hct 37.6%), Platelets 356,000/µL (normal platelet count, ruling out ITP/TTP/HELLP!). Smear: Normal red cells and platelets, no schistocytes.
- Chemistry & Urinalysis: Renal/liver panels normal. LDH 180 U/L, ESR 31 mm/hr. Urinalysis normal.
- Coagulation Profile: PT 12.0s (INR 1.0), Fibrinogen 534 mg/dL (normal, ruling out DIC!). aPTT 85.0s (severely prolonged! Normal <36s).
Hello, Chief Resident here.
Updated Key Findings: Normal platelet count and PT/INR rule out ITP, DIC, and HELLP. Confirmed hemarthroses and severe soft-tissue bleeding combined with an isolated, severely prolonged aPTT (85.0s) strongly indicate an acquired intrinsic pathway inhibitor in this postpartum patient.
Differential Diagnoses:
1. Acquired Hemophilia A (AHA) (80%): Postpartum FVIII autoantibodies present with an isolated prolonged aPTT and severe deep tissue/joint bleeding.
2. Lupus Anticoagulant / LA-Hypoprothrombinemia (10%): Prolongs aPTT; can cause bleeding if associated with Factor II deficiency.
3. Acquired Factor IX/XI Inhibitor or Severe AvWS (10%): Rare acquired factor-specific inhibitors or profound vWF depletion mimicking severe FVIII deficiency.
Prioritized Next Steps:
1. 1:1 aPTT Mixing Study (Immediate & 2-hour 37°C Incubation): Test for time-dependent inhibitor activity (classic for FVIII autoantibodies).
2. Factor VIII, IX, XI, XII Activity Levels: Confirm specific Factor VIII activity deficit (<1% expected).
3. Nijmegen-Bethesda Assay: Quantify inhibitor titer.
4. Bypassing Agents: Administer rFVIIa or aPCC promptly for hemarthrosis/active bleeding.
5. Immunosuppressive Therapy: Plan immediate high-dose corticosteroids ± rituximab upon diagnostic confirmation.
Hello Attending Consultant here
Critique: Correctly discards ITP/DIC via normal platelets/PT/fibrinogen. Overstates LA-HPS likelihood (bleeding rare without hypoprothrombinemia). Mixing study essential but must specify incubated failure-to-correct. Bypassing agents appropriately prioritized; omit empiric FVIII until titer known. No plan for inhibitor kinetics or malignancy screen.
Top 3 DDx:
1. Postpartum acquired hemophilia A (FVIII inhibitor)
2. Lupus anticoagulant-hypoprothrombinemia syndrome
3. Acquired FIX inhibitor
Specific points:
1. Immediate + 2-h incubated 1:1 mixing; expect time-dependent non-correction.
2. STAT FVIII/FIX/FXI levels + Nijmegen-Bethesda pre-therapy.
3. Start rFVIIa 90 µg/kg q2h or aPCC now for hemarthroses—do not await assays.
4. Add vWF Ag/activity and DRVVT to exclude AvWS/LA.
5. Initiate prednisone 1 mg/kg + rituximab 375 mg/m² once AHA confirmed.
6. Serial FVIII/aPTT q12h; avoid FVIII concentrates if titer >5 BU.
7. SPEP + postpartum pelvic US to exclude antigenic triggers.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Acquired Hemophilia A (postpartum) — an isolated, severely prolonged aPTT with normal PT, platelets, and fibrinogen, combined with hemarthroses and deep soft-tissue bleeding, is classic for a Factor VIII autoantibody.
Key Pivot: The aPTT is dramatically prolonged while every "consumptive/platelet" cause (ITP, TTP, DIC, HELLP) is excluded by normal counts and smear. Bleeding phenotype (joints, muscle, skin) — not mucosal — points to a factor inhibitor, not a platelet disorder.
Differentials:
- AHA — best fit; postpartum is the peak demographic, and FVIII inhibitors produce exactly this pattern.
- LA–hypoprothrombinemia syndrome — post-viral trigger and aPTT prolongation fit, but PT/INR is normal, arguing against factor II depletion. Check DRVVT and factor II.
- Acquired FIX/XI inhibitor or AvWS — plausible but far rarer; factor assays resolve this.
Most Important Next Move: Immediate + 2-hour incubated 1:1 mixing study, factor VIII/IX/XI levels, DRVVT, and Nijmegen-Bethesda titer. Concurrently, initiate bypassing agent therapy for active hemarthroses — do not wait for titers.
Teaching Pearl: AHA bleeding is often more subcutaneous/soft-tissue and less purely articular than congenital hemophilia; the hallmark lab clue is an isolated aPTT that fails to correct on incubated mixing.
Stage 3: Coagulation Mixing Study, Factor VIII Activity & Bethesda Assay (Timestamp: Hospital Days 1-2)
Coagulation Mixing Study & Assays:
- 1:1 mixing of patient plasma with normal control plasma yielded an initial aPTT of 55s, which rose to 64s after 30-minute incubation at 37°C (failure to correct, establishing a time- and temperature-dependent acquired circulating inhibitor!).
- Antiphospholipid & Specific Factor Assays:
- Lupus Anticoagulant Screening: Hexagonal phase test and dRVVT ratio (1.0) confirmed NO lupus anticoagulant.
- Factors IX, XI, XII & vWF: Normal.
- Factor VIII Activity Assay: Factor VIII activity <1% (normal 50–150%).
- Bethesda Inhibitor Assay: Factor VIII Inhibitor level = 23 Bethesda Units (BU) (high-titer acquired autoantibody!).
Unifying Diagnosis: Postpartum Acquired Hemophilia A (Acquired Factor VIII Inhibitor).
Hello, Chief Resident here.
Updated Key Findings: Time/temperature-dependent non-correction on aPTT mixing study, severe FVIII deficiency (<1%), negative lupus anticoagulant, and high-titer inhibitor at 23 Bethesda Units (BU), confirming Postpartum Acquired Hemophilia A (AHA).
Differential Diagnoses:
1. Postpartum Acquired Hemophilia A (95%): Definitive diagnosis confirmed by severe FVIII suppression (<1%) and high-titer neutralizing autoantibody (23 BU).
2. Acquired von Willebrand Syndrome (3%): Excluded by normal vWF activity and isolated high-titer FVIII inhibitor.
3. Systemic Autoimmune-Associated Coagulopathy (2%): Secondary inhibitor secondary to underlying SLE/RA; less likely given isolated clinical presentation.
Prioritized Management & Next Steps:
1. Immediate Hemostatic Control: Administer bypassing agents—recombinant Factor VIIa (rFVIIa 90 µg/kg q2–3h) or Activated Prothrombin Complex Concentrate (aPCC)—for severe hemarthroses. Avoid FVIII concentrates due to high-titer inhibitor (>5 BU).
2. Inhibitor Eradication: Initiate combination immunosuppression promptly with Prednisone (1 mg/kg/day) plus Rituximab (375 mg/m² weekly for 4 doses).
3. Supportive Precautions: Strictly avoid IM injections, NSAIDs, antiplatelet agents, and unnecessary invasive procedures; apply rest and cold compresses to affected joints.
4. Monitoring: Follow serial aPTT and FVIII activity to assess eradication response.
Hello Attending Consultant here
Critique: Diagnosis locked correctly. Plan appropriately prioritizes bypassing agents over FVIII concentrates given 23 BU titer. Under-emphasizes need for early combination IST intensity and omits thromboprophylaxis once FVIII recovers; no contingency for refractory bleeding or inhibitor rebound. Rituximab dosing/schedule needs explicit confirmation; monitoring cadence too vague.
Top 3 DDx:
1. Postpartum acquired hemophilia A (FVIII inhibitor, confirmed)
2. Transient postpartum autoantibody (self-limited variant)
3. Occult autoimmune/lymphoproliferative-associated AHA
Specific points:
1. Continue rFVIIa 90 µg/kg q2h or aPCC 50–100 U/kg q8–12h until hemostasis; taper per clinical response.
2. Confirm Nijmegen-modified Bethesda; recheck titer day 3–5.
3. Start prednisone 1 mg/kg + rituximab 375 mg/m² weekly ×4 immediately.
4. Add cyclophosphamide only if no FVIII rise by week 3–4.
5. Serial FVIII/aPTT q12–24h; target FVIII >50% before ambulation.
6. VTE prophylaxis once FVIII >30–50% and bleeding controlled.
7. Screen SPEP/CT and counsel on future pregnancy recurrence risk (~20%).
Hello, Expert Clinician here.
Best Unifying Diagnosis: Postpartum Acquired Hemophilia A — now laboratory-confirmed with a time- and temperature-dependent inhibitor, FVIII activity <1%, and a high-titer inhibitor (23 BU). Diagnosis is definitive; this is no longer a differential exercise.
Key Pivot: The mixing study distinguishes inhibitor from deficiency: failure to correct after incubation, plus isolated FVIII loss with normal FIX/XI/XII/vWF, excludes lupus anticoagulant and other factor defects.
Remaining Differentials:
- AHA (postpartum) — confirmed.
- Secondary AHA (occult autoimmune/lymphoproliferative) — worth screening, but the postpartum trigger is most parsimonious.
- Transient postpartum inhibitor — possible; may remit spontaneously, but 23 BU warrants active treatment.
Most Important Next Move: Dual-track management — (1) hemostatic control with bypassing agents (rFVIIa or aPCC) for active hemarthroses, since FVIII concentrates are futile at >5 BU; (2) inhibitor eradication with corticosteroids plus rituximab. Monitor serial FVIII activity and inhibitor titers; screen for occult malignancy/autoimmune triggers.
Teaching Pearl: AHA has two therapeutic goals that must run concurrently — stop the bleed (bypassing agents) and kill the clone (immunosuppression). Treating only the hemorrhage leaves the inhibitor — and the risk — intact.
Stage 4: Emergency Bypassing Agents & Combination Immunosuppression (Timestamp: Hospital Days 3-5)
Emergency Hemostatic Control & Readmission Management:
- Initiated Recombinant Activated Factor VII (rFVIIa) at 90 µg/kg IV every 3 hours to bypass Factor VIII inhibition and stop hemarthroses/hematoma expansion.
- Initiated High-Dose Corticosteroids: Prednisone 1 mg/kg/day IV/oral.
- Readmission Event: 2 Days Post-Discharge, presented with an expanding left thigh hematoma. Switched to Activated Prothrombin Complex Concentrate (aPCC / FEIBA) 75 µg/kg IV every 6 hours + initiated Rituximab (375 mg/m² weekly x 6 doses). Bleeding stabilized rapidly.
Hello, Chief Resident here.
Updated Key Findings: Confirmed postpartum AHA complicated by breakthrough bleeding (expanding left thigh hematoma) on rFVIIa, successfully managed by switching to aPCC (FEIBA) and escalating to dual immunosuppression (Prednisone + Rituximab) with rapid hemostatic stabilization.
Probability-Based Diagnoses:
1. Refractory High-Titer Postpartum Acquired Hemophilia A (90%): High-titer inhibitor (23 BU) causing initial bypassing-agent resistance, now responding to aPCC and combination IST.
2. Secondary AHA Unmasking Systemic Autoimmunity (10%): Underlying autoimmune disease (e.g., SLE) driving persistent autoantibody production.
Prioritized Management & Next Steps:
1. Hemostatic Maintenance & Taper: Continue aPCC (75 U/kg q6–8h), tapering as hematoma resolves; monitor closely for VTE/DIC risks.
2. Inhibitor Eradication: Complete the weekly Rituximab protocol (375 mg/m²) and maintain high-dose Prednisone until FVIII activity recovers.
3. Serial Monitoring: Draw weekly aPTT, Factor VIII activity, and Bethesda titers to document immune response and remission.
4. Infection Prophylaxis: Initiate Pneumocystis jirovecii (TMP-SMX) and fungal prophylaxis while on potent dual IST.
5. Thromboprophylaxis Plan: Initiate VTE prophylaxis once Factor VIII activity increases above 30–50% and active bleeding ceases.
Hello Attending Consultant here
Critique: Appropriate aPCC switch after rFVIIa breakthrough; dual IST correctly escalated. Overextends rituximab to 6 doses (standard 4); vague aPCC taper and thrombosis surveillance. Omits FVIII recovery thresholds for ambulation and secondary cause re-screen. Infection ppx timely but no antifungal duration specified.
Top 3 DDx:
1. High-titer postpartum AHA (breakthrough on rFVIIa)
2. Refractory AHA (needs 2nd-line IST)
3. Secondary AHA (occult autoimmunity/lymphoproliferative)
Specific points:
1. Continue aPCC 75 U/kg q6–12h; taper strictly by hematoma size/clinical hemostasis.
2. Limit rituximab to 375 mg/m² weekly ×4; reassess titer week 4.
3. Add cyclophosphamide if FVIII remains <10% by day 21.
4. Serial FVIII/aPTT/Bethesda q48–72h; target FVIII >50% before weight-bearing.
5. VTE ppx (LMWH) once FVIII >30% and bleeding quiescent; watch aPCC-related thrombosis.
6. PCP ppx (TMP-SMX) + short-course antifungal while on dual IST.
7. Repeat SPEP/ANA and pelvic imaging to exclude persistent antigenic drive.
Hello, Expert Clinician here.
Best Unifying Diagnosis: High-titer postpartum Acquired Hemophilia A with breakthrough bleeding on initial bypassing therapy — a recognized treatment challenge, not a diagnostic failure. The switch from rFVIIa to aPCC is rational, as roughly 10–15% of patients respond to one agent but not the other.
Key Pivot: The expanding thigh hematoma despite rFVIIa is the critical management inflection: it mandates (1) switching the bypassing agent class and (2) escalating immunosuppression immediately rather than waiting for first-line steroids alone.
Remaining Differentials:
- High-titer AHA (primary) — dominant; 23 BU predicts slower eradication and breakthrough events.
- Refractory/secondary AHA — consider occult autoimmune or lymphoproliferative drivers if inhibitor persists beyond 4 weeks.
- aPCC-related thrombosis — the emerging risk to monitor during therapy.
Most Important Next Move: Continue aPCC with clinical tapering, complete rituximab, and track serial FVIII activity and Bethesda titers every 48–72 hours. Add cyclophosphamide if FVIII remains <10% by week 3. Institute VTE prophylaxis once FVIII exceeds ~30–50% and bleeding is controlled.
Teaching Pearl: In AHA, bypassing agents have no reliable laboratory monitor — dosing is empiric and clinical. Failure of one agent (rFVIIa) warrants switching to the other (aPCC), never combining them, due to catastrophic thrombosis risk.
Stage 5: Complete Remission & Long-Term Factor VIII Recovery (Timestamp: Follow-up & Discharge)
Clinical Course & Follow-up Outcome:
- Prednisone tapered over 3 months; completed 6 doses of Rituximab.
- 8 Weeks Post-Treatment: aPTT normalized to 35 seconds; Factor VIII activity recovered to 54%.
- 2-Year Follow-up: Patient remains completely asymptomatic with no further bleeding episodes, stable aPTT (39s), and Factor VIII activity maintained at 50–60%, confirming complete remission of Postpartum Acquired Hemophilia A.
Hello, Chief Resident here.
Updated Key Findings: Complete clinical and laboratory remission of Postpartum Acquired Hemophilia A following dual immunosuppression (Prednisone + Rituximab), with normalized aPTT (35–39s), sustained Factor VIII activity (50–60%), and no bleeding recurrence at 2-year follow-up.
Probability-Based Diagnoses:
1. Resolved Postpartum Acquired Hemophilia A in Complete Remission (98%): Confirmed by complete inhibitor eradication, normalized aPTT, and sustained Factor VIII activity (>50%) over 24 months.
2. Risk of Future Relapse or Gestational Recurrence (2%): Small residual risk of autoantibody re-emergence with subsequent pregnancies or future systemic autoimmune triggers.
Next Steps & Recommendations:
1. Pre-conception Counseling: Educate patient on the ~20% risk of AHA recurrence in subsequent pregnancies; require close joint hematology-obstetrics monitoring for any future gestations.
2. Pragmatic Monitoring: Discontinue all immunosuppression. Obtain baseline aPTT and Factor VIII levels prior to any planned surgical/invasive procedures or if unusual bruising develops.
3. Long-Term Prognosis: Reassure the patient of her excellent long-term outlook while advising prompt evaluation if systemic or bleeding symptoms recur.
Hello Attending Consultant here
Critique: Correctly declares complete remission with sustained FVIII 50–60% and normalized aPTT. Overstates residual risk framing; under-emphasizes need for lifelong procedural alerts and explicit relapse surveillance intervals. Pre-conception counseling appropriate but omits inhibitor re-screening protocol and contraception advice during residual IST effects. No plan for bone-density or infection sequelae post-prolonged steroids/rituximab.
Top 3 DDx:
1. Postpartum AHA in durable complete remission
2. Latent inhibitor with risk of late relapse
3. Secondary AHA unmasked by future autoimmunity/pregnancy
Specific points:
1. Confirm final Nijmegen-Bethesda <0.6 BU; archive baseline FVIII/aPTT.
2. Annual aPTT/FVIII for 2–3 years, then prn for surgery/trauma/bruising.
3. MedicAlert + hematology letter for all future procedures; avoid elective IM/NSAIDs.
4. Pre-conception: recheck FVIII/inhibitor titer; multidisciplinary OB-heme plan; ~10–20% recurrence risk.
5. DEXA + calcium/vit D given prolonged steroids; update vaccinations post-rituximab.
6. Counsel on infection vigilance (hypogammaglobulinemia risk) for 12 months.
7. Document spontaneous remission potential but retain low-threshold re-evaluation.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Postpartum Acquired Hemophilia A in durable complete remission — sustained FVIII recovery (50–60%), normalized aPTT, and two years of bleed-free follow-up confirm eradication of the autoantibody. This represents a favorable, expected outcome for postpartum AHA, which carries the best remission rates (~70–90%) among all AHA etiologies.
Key Pivot: The case arc is now complete — the defining feature of postpartum AHA is its favorable prognosis, distinguishing it from malignancy- or autoimmune-associated AHA, where remission is harder to achieve and relapse more common.
Remaining Considerations:
- Relapse — occurs in ~20%, typically within the first year; two years of stability is highly reassuring.
- Future pregnancy recurrence — the single most important counseling point; inhibitor may re-emerge postpartum.
- Secondary causes — no evidence of occult autoimmunity or lymphoproliferative disease over two years makes this exceedingly unlikely.
Most Important Next Move: Transition to surveillance: annual FVIII/aPTT for 2–3 years, MedicAlert documentation, and formal pre-conception counseling with hematology-obstetric co-management for any future pregnancy. Address corticosteroid sequelae (bone health) and post-rituximab immune recovery.
Teaching Pearl: Complete remission in AHA is defined as FVIII >50% plus undetectable inhibitor off immunosuppression. Postpartum AHA uniquely offers patients an excellent prognosis — but the next pregnancy is always the test.